Rare ERBB2 kinase domain mutations have recently been suggested to serve as predictive markers for ErbB2-targeted therapy in the absence of ERBB2 amplification [25], indicating that rare mutations may have clinical relevance in high-incidence cancers such as breast cancer. Here, ERBB2 is linked to breast carcinoma.